Alembic Pharmaceuticals Ltd

Small Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Alembic Pharmaceuticals has commenced sales of Pivya (pivmecillinam) tablets in the US, marking its entry into the branded pharmaceutical market targeting uncomplicated urinary tract infections in women.

Alembic Launches First Branded Antibiotic in US - 06 Mar, 2026

Alembic Pharmaceuticals has received USFDA approval for Lamotrigine Orally Disintegrating Tablets, enhancing its portfolio in the US generics market with a projected market size of $27 million.

Alembic Pharma Secures USFDA Approval for Lamotrigine - 26 Feb, 2026

Alembic Pharmaceuticals has received final USFDA approval for Efinaconazole Topical Solution, 10%, a significant addition to its generics portfolio, with a projected market size of $500 million.

Alembic Pharma Secures USFDA Approval for Antifungal - 24 Feb, 2026

Alembic Pharmaceuticals received two observations from the USFDA following an inspection of its Karakhadi injectable facility. The company will respond promptly, maintaining its commitment to quality standards.

Alembic Pharma Faces USFDA Observations at Facility - 19 Feb, 2026

Alembic Pharmaceuticals achieved a 6% growth in its US generics business, reaching ₹553 crore, aided by new product launches and volume expansion despite pricing pressures.

Alembic Pharmaceuticals Reports Strong Growth in US Market - 08 Feb, 2026

Alembic Pharmaceuticals received USFDA approval for a Parkinson's treatment, plans new product launches, but shares fell 4% due to a profit miss.

Alembic Pharmaceuticals Faces Mixed Market Reactions - 06 Feb, 2026

Alembic Pharmaceuticals reported a decline in net profit for Q3 FY26 due to a one-time charge, despite revenue growth. The company will miss initial semaglutide launches but is exploring partnerships in India.

Alembic Pharmaceuticals Reports Q3 Results Amid Market Challenges - 05 Feb, 2026

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Foreign Institutions have increased holdings from 4.05% to 4.24% in Dec 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Up

In the last 1 year, Torrent Pharmaceuticals Ltd has given 40.6% return, outperforming this stock by 54.8%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

Against Peers

In the last 3 years, Torrent Pharmaceuticals Ltd has given 185.3% return, outperforming this stock by 146.9%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Promoters holdings remained unchanged at 69.74% of holdings in Dec 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

Netprofit is down for the last 2 quarters, 184.71 Cr → 132.97 Cr (in ₹), with an average decrease of 28.0% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Down

Revenue is down for the last 2 quarters, 1.91K Cr → 1.89K Cr (in ₹), with an average decrease of 1.4% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Fall

Retail Investor have decreased holdings from 9.92% to 9.85% in Dec 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Mutual Funds have decreased holdings from 8.55% to 8.22% in Dec 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Down

In the last 3 months, APLLTD stock has moved down by -19.5%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Dip

BSE Healthcare

Nifty MidSmallcap 400

S&P BSE 250 SmallCap

Nifty Smallcap 250

Nifty 500

S&P BSE 400 MidSmallCap

BSE 500

Kotak Small Cap Direct Growth

DSP Midcap Fund Direct Plan Growth

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth

DSP Small Cap Fund Direct Plan Growth

Axis Small Cap Fund Direct Growth

Alembic Pharmaceuticals Ltd’s net profit fell -3.94% since last year same period to ₹132.97Cr in the Q3 2025-2026. On a quarterly growth basis, Alembic Pharmaceuticals Ltd has generated -28.01% fall in its net profits since last 3-months.

Alembic Pharmaceuticals Ltd Earnings Results

In the quarter ending March 2025, Alembic Pharmaceuticals Ltd has declared dividend of ₹11.00 per share on 06 May 2025 - translating a dividend yield of 3.11%.

Name	Value	Action
MACD level (12,26)	-1.52	Bullish
CCI (20)	-109.1	Bullish
RSI (14)	40.03	Neutral
Momentum (10)	-2.15	Bearish
ADI (14)	29	Bearish
Ultimate Oscillator (7,14,28)	41.75	Neutral

Name	Value	Action
SMA (20)	693.54	Bearish
EMA (20)	693.71	Bearish
VWMA (20)	692.97	Bearish
SMA (50)	697.5	Bearish
EMA (50)	697.36	Bearish
SMA (200)	708.64	Bearish
EMA (200)	705.76	Bearish
KAMA (200)	696.75	Bearish
DEMA (200)	701.45	Bearish

Alembic Pharmaceuticals Ltd (APLLTD)

Summary

Overall

Oscillators

Moving Averages